Table 3.
Relationship between clinical characteristics and irinotecan-related toxicities
| Characteristics | Neutropenia grade, n (%)
|
P-value | Diarrhea grade, n (%)
|
P-value | ||
|---|---|---|---|---|---|---|
| 0–II | III–IV | 0–II | III–IV | |||
| Age (years) | ||||||
| ≤60 | 14 (29.2) | 12 (25.0) | 0.961 | 23 (47.9) | 3 (6.3) | 1.000 |
| >60 | 12 (25.0) | 10 (20.8) | 19 (39.5) | 3 (6.3) | ||
| Sex | ||||||
| Male | 12 (25.0) | 13 (27.1) | 0.371 | 22 (45.7) | 3 (6.3) | 1.000 |
| Female | 14 (29.2) | 9 (18.8) | 20 (41.7) | 3 (6.3) | ||
| ECOG | ||||||
| 0 | 18 (37.5) | 15 (31.2) | 0.938 | 29 (60.4) | 4 (8.3) | 1.000 |
| 1 | 8 (16.7) | 7 (14.6) | 13 (27.1) | 2 (4.2) | ||
| Line of treatment | ||||||
| Second line | 20 (41.7) | 16 (33.3) | 0.738 | 32 (66.7) | 4 (8.3) | 0.631 |
| Third line | 6 (12.5) | 6 (12.5) | 10 (20.8) | 2 (4.2) | ||
| Current treatment | ||||||
| FOLFIRI | 15 (31.2) | 18 (37.5) | 0.072 | 30 (62.4) | 3 (6.3) | 0.360 |
| Irinotecan monotherapy | 11 (22.9) | 4 (8.3) | 12 (25.0) | 3 (6.3) | ||
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FOLFIRI, a chemotherapy regimen containing folinic acid (FOL), fluorouracil (F), and irinotecan (IRI).